http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2534331-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9237fdf6dca9ac365fc5166858e7862 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D515-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D515-22 |
| filingDate | 2011-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ddaf05a1ca095d1687b379759345d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1d7228febe383a7eb8882be265452fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6b8283e66d6a8a254b5e40f17489f3e |
| publicationDate | 2015-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2534331-T3 |
| titleOfInvention | Synthetic process for the production of ecteinascidin compounds and intermediates |
| abstract | A process for the synthesis of a compound of formula I ** Formula ** wherein: R1 and R4 are independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, alkynyl of C2-C12 substituted or unsubstituted, C (> = O) Ra, C (> = O) ORb, C (> = O) NRcRd, and a protective group for OH; R2 is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, C (> = O) Ra, C (> = O) ORb, C (> = O) NRcRd, and a protective group for amino; R3 is CN or OH; R5 and R6 together with the carbon atom to which they are attached form a group: (a) C (> = O); (b) CH (OR7) or CH (NR8R9) wherein R7 is selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and a OH protecting group; and R8 and R9 are independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted heterocyclic group or unsubstituted and a protective group for amino; (c) a group of the formula: ** Formula ** wherein X1 and X2 are independently selected from hydrogen and substituted or unsubstituted C1-C12 alkyl; R10 and R11 are independently selected from hydrogen, C (> = O) Ra, C (> = O) ORb, C (> = O) NRcRd, substituted or unsubstituted C1-C12 alkyl, substituted or substituted C2-C12 alkenyl unsubstituted, and substituted or unsubstituted C2-C12 alkynyl; or (d) a group of formula: ** Formula ** where Y1 is selected from hydrogen, ORb, OC (> = O) Ra, OC (> = O) ORb, OC (> = O) NRcRd, SRe, SORa, SO2Ra, C (> = O) Ra, C (> = O) ORb, C (> = O) NRcRd, NO2, NRcRd, N (Rc) C (> = O) Ra, N (Rc) -ORb , C (Ra)> = NORb, N (Rc) C (> = O) ORb, N (Rc) C (> = O) NRcRd; CN, halogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclic group; Y2 and Y3 are independently selected from hydrogen and substituted or unsubstituted C1-C12 alkyl; R12 and R13 are independently selected from hydrogen, C (> = O) Ra, C (> = O) ORb, C (> = O) NRcRd, substituted or unsubstituted C1-C12 alkyl, substituted or substituted C2-C12 alkenyl unsubstituted, substituted or unsubstituted C2-C12 alkynyl; and each Ra is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, and substituted heterocyclic group or without replacing; each Rb is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and a protective group for OH; each Rc and Rd are independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted heterocyclic group or unsubstituted and a protective group for amino; each Re is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and a protective group for SH; or a pharmaceutically acceptable salt thereof, wherein the process comprises the step of reducing a quinone of formula II followed by alkylation of the resulting hydroquinone with a suitable electrophilic reagent to give a compound of formula IIa: ** Formula ** |
| priorityDate | 2010-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 686.